Catalog No.
Product Name
Application
Product Information
Citations
-
IL-2 secretion inhibitor
BC12-4 is a potent inhibitor of interleukin-2 (IL-2) secretion, primarily acting on immune cell signaling pathways. This compound exhibits immunomodulatory activity, making it valuable in the study of cytokine regulation and immune responses. BC12-4 is suitable for research applications focused on autoimmune diseases, transplantation, and cancer immunotherapy. -
IL-1/β-transferase Inhibitor
Pentenocin A is an inhibitor of IL-1β-transferase, also known as interleukin-1 converting enzyme (ICE). This compound displays weak inhibitory activity against the processing of pro-inflammatory cytokine IL-1β, making it useful for studies related to inflammation and immune response. Its applications can extend to research exploring pathways involved in cytokine maturation and signaling, contributing to the understanding of various inflammatory diseases. -
IL-2 Inhibitor
Digitoxigenin-3-O-β-D-quinovoside is a potent interleukin-2 (IL-2) inhibitor, exhibiting an IC50 value of 52 nM. This cardiac glycoside is derived from the plant Elaeodendron australe var. integrifolium. It is useful in research applications focused on immune modulation and the investigation of IL-2 signaling pathways, providing valuable insights into related therapeutic areas. -
IL-1β Inhibitor
Shegansu B is a potent inhibitor of IL-1β, demonstrating significant inhibition of IL-1β expression in LPS-induced THP-1 cells, achieving an inhibition rate of 64.74%. This compound exhibits noteworthy anti-inflammatory activity, making it a valuable tool for research applications focused on inflammation and immune response modulation. Its selective targeting of IL-1β positions Shegansu B as an important reagent for studies aimed at understanding inflammatory processes and potential therapeutic interventions. - Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
-
anti-inflammatory agent
Balsalazide is an anti-inflammatory agent for treatment of Inflammatory Bowel Disease. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. -
interleukin-5 receptor antagonist
YM-90709 is an interleukin-5 receptor antagonist. YM-90709 inhibits the binding of IL-5 to its receptor on peripheral human eosinophils and butyric acid-treated eosinophilic HL-60 clone 15 cells, with IC50 values of 1.0 and 0.57 microM, respectively. -
IL-1 inhibitor
AS101, a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme. - Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.
-
Smurf1 inhibitor
Smurf1-IN-A01 (A01) is an ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smurf1) inhibitor with a kd of 3.664 nM, which increases BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. -
IL-2 inducer
Nosantine racemate is the racemate of Nosantine. Nosantine is an inducer of IL-2 or enhancer of IL-2 induction by phytohemagglutinin (PHA). -
IL-15 inhibitor
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. - Dexanabinol exhibits not only the antioxidant and neuroprotective activities in brain but also anti-inflammatory activity by inhibiting NF-κB and decreasing cytokines such as TNFα and interleukin-6, which could ensure the integrity of BBB and reduce cell apoptosis and death.
-
IL-2 synthesis inhibitor
NFAT Transcription Factor Regulator-1 is an IL-2 synthesis inhibitor with an IC50 of 182 nM. -
IL receptor agonist
NO-prednisolone is a nitric oxide (NO)-releasing derivative of Prednisolone. NO-prednisolone potently stimulates IL-10 production in vivo. -
T cell activator
beta-Interleukin I (163-171), human, a peptide. Interleukins are a group of cytokines (secreted proteins/signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). -
anti-cancer agent
Ginsenoside Rc, isolated from Panax ginseng, may exert various activities including anti-cancer, anti-inflammatory, antiobesity, and anti-diabetic effects. - Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
-
IL-1β Processing Inhibitor
CP-424174 is a reversible inhibitor of IL-1β processing, acting with an IC50 of 210 nM. By indirectly inhibiting the NLRP3 inflammasome, CP-424174 plays a critical role in modulating inflammatory responses. This compound is useful for research applications focused on understanding the mechanisms of inflammation and potential therapeutic interventions in inflammatory diseases. -
Anti-PD-1 Antibody/IL-21 Mutein
Latikafusp is a bifunctional fusion protein that functions as an anti-PD-1 antibody paired with an IL-21 mutein. This compound is designed to stimulate the IL-21 pathway specifically in PD-1+ cells, enhancing the priming and persistence of cytotoxic and memory T cells to promote anti-tumor immunity. Latikafusp is particularly relevant in research focused on solid tumors and has the potential to elicit immunogenicity-mediated responses. -
IL-17A Inhibitor
LY3509754 is a potent IL-17A inhibitor, demonstrating IC50 values of less than 9.45 nM in alphaLISA assays and 9.3 nM in HT-29 cell assays. This compound's selective inhibition of IL-17A makes it a valuable tool for investigating the role of IL-17A in inflammatory diseases and immune responses. Its use in research applications can help elucidate the therapeutic potential for conditions associated with IL-17A signaling. -
IL-17A antagonist
IL-17A antagonist 1 is a potent inhibitor of the interleukin-17A cytokine, demonstrating a binding affinity (Kd) of 0.66 μM and an inhibitory concentration (IC50) of 1.14 μM. This compound effectively modulates IL-17A signaling, making it a valuable tool for studying inflammatory responses and autoimmune disorders. It is suitable for research applications focused on understanding the role of IL-17A in various biological processes and therapeutic interventions. -
IL-15 Agonist
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain fused with human IgG1 Fc, serving as an IL-15 superagonist. This compound forms a complex with the IL-15 antibody Nogapendekin alfa, enhancing anti-CD20 monoclonal antibody-mediated natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept significantly promotes degranulation and interferon-gamma (IFNγ) production in NK cells, making it a valuable tool for research in immunotherapy and cancer treatment strategies. -
IL-17 Modulator
IL-17 Modulator 4 is a proagent of IL-17 Modulator 1, serving as an IL-17 inhibitor targeting the interleukin-17 pathway. This compound exhibits potent modulation of IL-17A and is significant for research into IL-17A mediated diseases, including various inflammatory and autoimmune conditions, as well as infectious diseases and cancer. Its application in preclinical studies may enhance understanding of the therapeutic potential in these pathologies. -
IL-2R Agonist
Nemvaleukin alfa is an IL-2 fusion protein that selectively targets intermediate-affinity IL-2 receptors (IL-2R). Its mechanism involves activating natural killer (NK) cells and effector T cells, thereby enhancing immune responses. This reagent is utilized in cancer research to investigate immune modulation and therapeutic strategies aimed at improving anti-tumor immunity. -
IL-22 Activator
Efmarodocokin alfa is a fusion protein comprising human IL-22 and the IgG4 crystallizable fragment, functioning primarily as an IL-22 activator. This reagent enhances IL-22 signaling pathways, contributing to the modulation of immune responses. It is particularly relevant for research applications focused on severe COVID-19 pneumonia, facilitating studies on therapeutic strategies that leverage IL-22 in inflammation and tissue repair processes. -
IL-17 Modulator
IL-17 modulator 3 is a specific IL-17 modulator that targets the IL-17 signaling pathway, playing an essential role in immune regulation. It exhibits potential anti-inflammatory properties and is valuable for research into inflammatory conditions, cancer, and autoimmune diseases. This compound offers insights into the modulation of IL-17 related pathways in various biological contexts. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
IL-17A Antagonist
Simepdekinra is an IL-17A antagonist that plays a crucial role in modulating inflammatory responses. It demonstrates significant potential in the research of moderate to severe plaque-type psoriasis by inhibiting the activity of IL-17A, a key cytokine involved in the pathogenesis of this condition. Its application in preclinical studies provides valuable insights into therapeutic strategies targeting autoimmune skin diseases. -
IL-2/IL-2Rα Inhibitor
SP4206 is an inhibitor of the IL-2/IL-2Rα interaction, exhibiting high-affinity binding to IL-2 with a dissociation constant (Kd) of 70 nM. By effectively blocking the interaction with its natural receptor IL-2Rα, which has a Kd of 10 nM, SP4206 has significant potential for modulating immune responses. This compound is valuable for research applications focused on autoimmune diseases, cancer immunotherapy, and enhancing our understanding of IL-2-mediated signaling pathways. -
IL-18 Inhibitor
NSC80734 is an IL-18 inhibitor that effectively disrupts the binding of human IL-18 to ectromelia virus IL-18 binding protein (IL-18BP). This compound inhibits the IL-18-mediated production of interferon-gamma (IFN-γ), making it a valuable tool for studying the role of IL-18 in inflammatory processes and immune responses. NSC80734 is applicable in research focusing on cytokine signaling and related biological pathways. -
IL-17C/IL-17RE Interaction Inhibitor
Lib2-1 is a macrocyclic peptide that functions as an inhibitor of the IL-17C/IL-17RE interaction. This compound demonstrates significant potential in modulating inflammatory responses, making it a valuable tool in the study of autoimmune and inflammatory diseases. Researchers can utilize Lib2-1 to investigate the underlying mechanisms of IL-17C signaling and its implications in various pathological conditions. -
IL-15 Agonist
Nogapendekin alfa (his tag) is a soluble protein subunit of a human interleukin-15 variant, acting as a potent superagonist of IL-15. It enhances the proliferation and survival of immune cells, making it valuable for various immuno-oncology studies. In combination with Inbakicept, Nogapendekin alfa forms the IL-15 cytokine-antibody fusion protein N-803, which has demonstrated the ability to reduce tumor burden through the activation of natural killer (NK) cells and CD8+ T cells. This reagent is instrumental in research applications targeting cancer immunotherapy and immune response modulation. -
IL-17A Antagonist
IL-17A antagonist 3 is a selective inhibitor of IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. This compound effectively blocks the interaction of IL-17A with its receptor, leading to reduced downstream inflammatory responses. It is applicable in research focused on the pathophysiology of conditions such as psoriasis, rheumatoid arthritis, and other IL-17-mediated disorders. -
IL-17A Modulator
IL-17A modulator-2 selectively targets interleukin-17A (IL-17A), functioning as a potent inhibitor with a pIC50 of 8.3. This compound effectively modulates the biological activity of IL-17A, making it valuable for research into a variety of conditions linked with IL-17A dysregulation. Applications include investigations into autoimmune diseases, cancers, and neurodegenerative disorders where IL-17A plays a significant role in pathogenesis. -
IL-18 Inhibitor
NSC61610 is an inhibitor of interleukin-18 (IL-18) that disrupts the binding of human IL-18 to the ectromelia virus IL-18 binding protein (IL-18BP). It effectively inhibits the formation of the hIL-18:ectvIL-18BP complex, demonstrating an IC50 of approximately 6 µM. This compound is valuable for research applications involving inflammatory responses and the study of viral interactions with host immune mechanisms. -
IL-17A Modulator
IL-17A modulator-1 is a selective modulator of interleukin-17A (IL-17A) that inhibits its biological activity with a pIC50 of 8.2. This compound is valuable for research into diseases associated with dysregulation of IL-17A, including autoimmune disorders, cancers, and neurodegenerative diseases. Its ability to modulate IL-17A activity makes it a pertinent tool for studies investigating immune responses and therapeutic interventions. -
IL-1 Inhibitor
Lys-D-Pro-Thr is an IL-1β analogue, specifically targeting the positions 193-195 of the IL-1β protein. It acts as a potent inhibitor of IL-1, playing a critical role in regulating inflammatory responses. This reagent is valuable for research applications focused on inflammatory pathways, autoimmune diseases, and the modulation of cytokine signaling. -
IL-17A Inhibitor
Navepdekinra is a potent inhibitor of interleukin-17A (IL-17A), with an IC50 of 10.81 nM. By disrupting the interaction between IL-17A and its receptor, Navepdekinra effectively suppresses downstream pro-inflammatory signaling pathways. This compound has demonstrated efficacy in reducing arthritis symptoms in a collagen-induced arthritis rat model and is applicable to research in psoriasis, psoriatic arthritis, and ankylosing spondylitis. -
FAPα/IL-2Rβγ Immunocytokine
Simlukafusp alfa is an immunocytokine composed of an antibody targeting fibroblast activation protein α (FAPα) and a variant of interleukin-2 (IL-2) that selectively engages the IL-2 receptor βγ chain. This unique structure enhances the immune response against FAPα-expressing tumors while promoting T-cell activation and proliferation. Simlukafusp alfa is suitable for research applications focused on cancer immunotherapy and the study of tumor microenvironments, particularly in evaluating the efficacy of targeted immune modulation. -
IL-1 Antagonist
Goflikicept is an IL-1 antagonist that functions as a fusion protein, selectively binding to and neutralizing both IL-1β and IL-1α. This mechanism of action positions Goflikicept as a valuable tool for research focused on inflammatory conditions, particularly in the context of ST-segment elevation myocardial infarction (STEMI). Its ability to modulate IL-1 signaling pathways makes it relevant for studying various cardiovascular and autoimmune disorders. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling.
